Dissolution profiles of perindopril and indapamide in their fixed-dose formulations by a new HPLC method and different mathematical approaches

1. M. Gorostidi and A. De la Sierra, A combination therapy in hypertension, Adv. Ther.30 (2013) 320–336; DOI: 10.1007/s12325-013-0020-9.10.1007/s12325-013-0020-9Search in Google Scholar

2. D.K. Modi and C.N. Patel, Development and validation of spectrophotometric method for simultaneous estimation of perindopril and indapamide in combined dosage form by simultaneous equation, Eurasian J. Anal. Chem. 6 (2011) 46–52.Search in Google Scholar

3. S.S. Kale, R.L. Bakal, A.V. Chandewar and R.S. Sakhare, Two wavelength method for estimation of indapamide and perindopril erbumine in combined tablet dosage form, Res. J. Pharm. Technol.4 (2011) 545–548.Search in Google Scholar

4. D.K. Modi and C.N. Patel, Development and validation of spectrophotometric method for simultaneous estimation of perindopril and indapamide in combined dosage form by absorbance correction method, Int. J. Pharm. Tech. Res.2 (2010) 411–416.Search in Google Scholar

5. N. Erk, Comparison of spectrophotometric and an LC method for the determination perindopril and indapamide in pharmaceutical formulations, J. Pharm. Biomed. Anal.26 (2001) 43–45; DOI: 10.1016/S0731-7085(01)00388-0.10.1016/S0731-7085(01)00388-0Search in Google Scholar

6. R. Tiwan, A. Jain, D. Maliwal and E. Toppo, Multicriteria optimization methodology in development of HPLC method for simultaneous estimation of indapamide and perindopril in bulk drug and its combined dosage form, Asian J. Pharm. Clin. Res.5 (2012) 50–53.Search in Google Scholar

7. J. Joseph, B. Philip and M. Sundarapandian, Method development and validation for simultaneous estimation of perindopril erbumine and indapamide by RP-HPLC in pharmaceutical dosage forms, Int. J. Pharm. Pharm. Sci. 3 (2011) 288–293.Search in Google Scholar

8. H. Jogia, U. Khandelwal, T. Gandhi, S. Singh and D. Modi, Development and validation of a stability-indicating assay method for simultaneous determination of perindopril and indapamide in combined dosage form by reversed-phase high-performance liquid chromatography, J. AOAC Int.93 (2010) 108–115.10.1093/jaoac/93.1.108Search in Google Scholar

9. A. A. Elshanawane, S. M. Mostafa and M. S. Elgawish, Development and validation of LC method for simultaneous determination of two binary mixtures containing indapamide, Chromatographia67 (2008) 837–840; DOI: 10.1365/s/10337-008-0600-z0009-5893/08/05.Search in Google Scholar

10. C. Graffner, Regulatory aspects of drug dissolution from a European perspective, Eur. J. Pharm. Sci.29 (2006) 288–293; DOI: 10.1016/j.ejps.2006.05.003.10.1016/j.ejps.2006.05.003Search in Google Scholar

11. T. O′Hara, A. Dunne, J. Butler and J. Devane, A review of methods used to compare dissolution profile data, Pharm. Sci. Technol. Today1 (1998) 214–223; DOI: 10.1016/S1461-5347(98)00053-4.10.1016/S1461-5347(98)00053-4Search in Google Scholar

12. P. Costa and J. M. S. Lobo, Modeling and comparison of dissolution profiles, Eur. J. Pharm. Sci.13 (2001) 123–133; DOI: 10.1016/S0928-0987(01)00095-1.10.1016/S0928-0987(01)00095-1Search in Google Scholar

13. N. Yuksel, A. E. Kanik and T. Baykara, Comparison of in vitro dissolution profiles by ANOVA-based, model dependent and –independent methods, Int. J. Pharm. 209 (2000) 57–67; DOI: 10.1016/S0378-5173(00)00554-8.10.1016/S0378-5173(00)00554-8Search in Google Scholar

14. R. M. Maggio, P. M. Castellano and T. S. Kaufman, A new principal component analysis-based approach for testing “similarity” of drug dissolution profiles, Eur. J. Pharm. Sci.34 (2008) 66–77; DOI: 10.1016/j.ejps.2008.02.009.10.1016/j.ejps.2008.02.009Search in Google Scholar

15. European Medicines Agency, Note for Guidance on the Investigation of Bioavailability and Bioequivalence, EMA CPMP/EWP/QWP/1401/98, July 2001; http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500003008&mid=WC0b01ac058009a3dc; access date April 10, 2015.Search in Google Scholar

16. Food and Drug Administration, Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), FDA, August 1997. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070237.pdf; last access date June 27, 2014.Search in Google Scholar

17. E. Adams, R. De Maesschalck, B. De Spiegeleer, Y. Vander Heyden, J. Smeyers-Verbeke and D. L. Massart, Evaluation of dissolution profiles using principal component analysis, Int. J. Pharm. 212 (2001) 41–53; DOI: 10.1016/S0378-5173(00)00581-0.10.1016/S0378-5173(00)00581-0Search in Google Scholar

18. European Pharmacopoeia 7.0, EDQM Council of Europe, Strasbourg 2010.Search in Google Scholar

19. Y. Zhang, H. Meirong, J. Zhou, A. Zou, W. Li, W. Yao and S. Xie, DDSolver: an add-in program for modeling and comparison of drug dissolution profiles, AAPS J.12 (2010) 263–271; DOI: 10.1208/s12248-010-9185-1.10.1208/s12248-010-9185-1289545320373062Search in Google Scholar

20. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Current Step 4 version, November 2005; http://www.ich.org/products/guidelines/quality/quality-single/article/validation-of-analytical-procedures-text-and-methodology.html; last access date April 15, 2014.Search in Google Scholar

21. The United States Pharmacopoeia USP 34, NF 29, USP Convention, Rockville 2011.Search in Google Scholar